Abstract
The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug-resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy
-
Adamantane / analogs & derivatives
-
Adamantane / pharmacology
-
Animals
-
Anti-Bacterial Agents / pharmacology
-
Antitubercular Agents / pharmacology*
-
Antitubercular Agents / therapeutic use
-
Drug Administration Schedule
-
Drug Resistance, Bacterial
-
Drug Therapy, Combination
-
Drugs, Investigational / pharmacology*
-
Drugs, Investigational / therapeutic use
-
Ethylenediamines / pharmacology
-
Extensively Drug-Resistant Tuberculosis / drug therapy
-
Fluoroquinolones / pharmacology*
-
Fluoroquinolones / therapeutic use
-
Humans
-
Isoniazid / therapeutic use
-
Mycobacterium tuberculosis / drug effects*
-
Nitroimidazoles / pharmacology
-
Oxazoles / pharmacology
-
Pyrazinamide / therapeutic use
-
Rifampin / therapeutic use
-
Treatment Refusal*
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Pulmonary / drug therapy
Substances
-
Anti-Bacterial Agents
-
Antitubercular Agents
-
Drugs, Investigational
-
Ethylenediamines
-
Fluoroquinolones
-
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine
-
Nitroimidazoles
-
OPC-67683
-
Oxazoles
-
pretomanid
-
Pyrazinamide
-
Adamantane
-
Isoniazid
-
Rifampin